ERBB2 and cardiac arrest: After 5 days, the patient suffered from progressive hypotension, bradycardia, and gastrointestinal bleeding that eventually led to cardiac arrest and treatment-related death.31 This clinical trial has since been terminated (the above patient was the first and only patient receiving the investigational ERBB2 CAR-T therapy).